INTRODUCTION {#s5}
============

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterised by synovitis and destruction of synovial joints, leading to severe disability and premature mortality.^[@R1]^ The introduction of disease-modifying antirheumatic drugs (DMARDs) in the treatment of patients with RA has led to improved management of RA, making not only (complete) symptom relief, but in addition the prevention of long-term structural damage the current goal of therapy.^[@R2]^ The prevention of structural damage is also recognised by the Food and Drug Administration (FDA)^[@R3]^ and the European Medicines Agency (EMA)^[@R4]^ as a separate claim for a drug and defines the disease-modifying capability of a drug.

To date, radiographs are still considered the most appropriate method to assess structural damage in RA. MRI is regarded as a supportive imaging method but is not yet accepted as an alternative for radiographs by the FDA and EMA.^[@R3]^ Validated radiographic scoring methods exist and are widely used for assessment and follow-up of joint damage in RA. Labelling for 'inhibition of radiographic progression' is granted to both synthetic and biological DMARDs (bDMARDs) based on randomised controlled trials (RCTs) in which retardation of structural progression is demonstrated using such validated scoring methods.

There is a general tendency for less radiographic progression in more recent RCTs.^[@R5]^ This may be due to: earlier, more effective treatment of patients included in RCTs, leading to less structural damage at baseline^[@R6]^; or to less exposure to placebo (control) therapy due to earlier rescue. These developments have made it challenging to demonstrate the superiority of new drugs in inhibiting radiographic progression in RCTs. For future RCTs, this will require even more careful selection of patients prone to radiographic progression and perhaps change in study design.^[@R5]^ In this context, an overview of data used to get a label for 'inhibition of structural damage' by pharmaceutical companies would be of interest. Existing reviews of radiographic data do not include trials of more recent bDMARDs and targeted synthetic DMARDs (tsDMARDs), such as certolizumab, golimumab, tocilizumab and janus kinase inhibitors,^[@R7]^ or do not consider methodological aspects of analysing radiographic data.^[@R6]^

The purpose of this overview was to summarise radiographic data in RCTs performed by pharmaceutical companies, usually to obtain the claim of radiographic inhibition, of all DMARDs approved for patients with RA. This can serve as a repository for the design including power calculations of future trials.

METHODS {#s6}
=======

This review is based on published articles reporting the results of RCTs for RA performed by pharmaceutical companies, in which the effects of new treatments on radiographic damage were evaluated. These trials were mostly used to obtain the registration as DMARDs for the respective treatment; however, some are pharmaceutical company-performed post-approval studies. A literature search on the topic was conducted in PubMed. The research question was translated into an epidemiological research question according to the PICO method (Patients, Intervention, Comparator and Outcome).^[@R8]^ Patients were defined as adults with RA according to the 1987 American College of Rheumatology (ACR) criteria^[@R9]^ or to the 2010 ACR criteria^[@R10]^; intervention was defined as any drug; comparator as placebo or another active drug; outcome was radiographic progression.

The literature search was carried out in PubMed. The database was searched using the following specific terms (synonyms and all possible combinations): rheumatoid arthritis, adalimumab, etanercept, infliximab, certolizumab, golimumab, anakinra, tocilizumab, rituximab, abatacept, tofacitinib, leflunomide, upadacitinib, baricitinib, peficitinib, ruxolitinib, filgotinib, ustekinumab, guselkumab, secukinumab, ixekizumab, canakinumab, brodalumab, sarilumab, secukinumab, sirukumab, radiographic, radiologic, structural or progression, Sharp, van der Heijde, Genant or Larsen. The search was limited to English language literature without a time limit. The last search was performed on February 6, 2020. The references of the selected articles were manually reviewed to identify additional relevant publications. Unpublished study enrolment dates were searched on ClinicalTrials.gov, fda.gov using, when available, the study identification number from publications. Pharmaceutical companies were also contacted to obtain unpublished data. Abstracts were not included as these contain insufficient detailed information.

The retrieved citations were managed using EndNote. One reviewer performed a selection based on titles and abstracts using predefined inclusion and exclusion criteria. The selected citations were discussed among two authors and included by consensus. To be included, articles had to contain data collected from any RCT performed by pharmaceutical companies for treatment registration (and their open-label extensions) or to further support the inhibition of radiographic progression, involving adult patients with RA (age \>18 years). Articles with the following characteristics were excluded: investigator initiated and strategy studies, pediatric population, non-RA, languages other than English, no radiographic results reported, review articles, guidelines papers, case reports, commentary or letters. Based on this screening, full-text articles were obtained for more detailed reviewing.

Data extraction {#s6-s1}
---------------

An electronic form was used for the data extraction. The study characteristics including study design, patient enrolment dates, all relevant baseline demographics, clinical characteristics and all baseline and follow-up radiographic data were recorded. Trials were divided into methotrexate (MTX)-naïve, MTX inadequate responder (IR), DMARDs IR, or tumour necrosis factor-alpha inhibitors (TNFi) IR populations. The Larsen method was included in the literature search; however, this was used only in a limited number of older RCTs for which we have also results with the Sharp method. Therefore, we decided to exclude reporting data based on the Larsen method. A detailed data extraction flow chart is depicted in [online supplementary figure 1](#SP1){ref-type="supplementary-material"}.

![Flow chart of the trial selection process.](rmdopen-2020-001277f01){#F1}
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RESULTS {#s7}
=======

A total of 1170 publications were identified in PubMed. Based on title and abstract review, 1002 publications were excluded because they did not include the population or intervention of interest, did not report radiographic results, were not randomised, controlled trials or were not performed by pharmaceutical companies. The remaining 168 publications were read full text. Of these, 104 manuscripts describing the results of 52 RA trials were included and were used for data extraction. A flow diagram summarising the screening and selection of articles is shown in [figure 1](#F1){ref-type="fig"}.

The 52 included RCTs are presented in [table 1](#T1){ref-type="table"}. The MTX-naïve group included 17 RCTs (2 of a conventional synthetic DMARD (csDMARD) (leflunomide), 10 of a TNFi (adalimumab, certolizumab, etanercept, golimumab, infliximab) and 5 of a non-TNFi bDMARD or tsDMARD (abatacept, baricitinib, rituximab, tocilizumab, tofacitinib). MTX was mostly used as comparator. The MTX IR group included 23 RCTs (12 trials of TNFi (adalimumab, certolizumab, etanercept, golimumab, infliximab, biosimilar of etanercept, biosimilar of infliximab) and 11 of non-TNFi bDMARD or tsDMARD (anakinra, abatacept, baricitinib, denosumab, peficitinib, sarilumab, tocilizumab, tofacitinib, upadacitinib)) again with MTX as the most frequently used comparator. MTX IR trials enrolled 77--651 patients in the comparator group and 85--651 patients in the treatment group. The DMARD IR group included 9 RCTs (1 csDMARD (leflunomide), 4 TNFi (certolizumab, etanercept, golimumab) and 4 non-TNFi bDMARDs and tsDMARDs (baricitinib, sirukumab, tocilizumab)), which included 91--556 patients in the comparator group and 102--557 patients in the treatment group. There were three trials conducted in a TNFi IR population investigating adalimumab, rituximab and secukinumab[,]{.ul} which studied 16--214 patients in the comparator group and 17--308 patients in the treatment group.

###### 

Randomised controlled trials included for review

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients population   Trial name              References   RA classfication criteria   ClinicalTrials.gov number   Enrollment\       Active drug   Comparator drug   Number of patients per treatment arm\
                                                                                                                     start date\*                                      comparator-active†
  --------------------- ----------------------- ------------ --------------------------- --------------------------- ----------------- ------------- ----------------- ---------------------------------------
  MTX naïve             US301/ULTRA             ^[@R11]^     1987                        --                          1995              LEF           PBO, MTX          118--182

                        MN302‡                  ^[@R11]^     1987                        --                          1994              LEF           MTX               487--498

                        ERA                     ^[@R12]^     1987                        --                          May 1997          ETN           MTX               217--208

                        ASPIRE§                 ^[@R13]^     1987                        --                          July 2000         IFX           MTX               282--363

                        PREMIER¶                ^[@R14]^     1987                        --                          December 2000     ADA           MTX               257--274

                        COMET‡                  ^[@R15]^     1987                        NCT00195494                 October 2004      ETN           MTX               263--265

                        GO-BEFORE§, ¶           ^[@R16]^     1987                        NCT00264537                 December 2005     GOL           MTX               160--159

                        IMAGE                   ^[@R17]^     1987                        NCT00299104                 January 2006      RTX           MTX               249--250

                        OPTIMA‡, \*\*           ^[@R18]^     1987                        NCT00420927                 December 2006     ADA           MTX               517--515

                        AGREE‡,§                ^[@R19]^     1987                        NCT00122382                 2005\*            ABA           MTX               253--256

                        HOPEFUL 1               ^[@R20]^     1987                        NCT00870467                 March 2009        ADA           MTX               163--171

                        FUNCTION                ^[@R21]^     1987                        NCT01007435                 October 2009      TCZ           MTX               287--292

                        PRIZE‡, \*\*            ^[@R22]^     1987                        NCT00913458                 October 2009      ETN           PBO, MTX          65--65

                        ORAL Start              ^[@R23]^     1987                        NCT01039688                 January 2010      TOF           MTX               186--397

                        C-OPERA‡, \*\*          ^[@R24]^     2010                        NCT01451203                 October 2011      CZP           MTX               157--159

                        C-EARLY‡, \*\*, ††      ^[@R25]^     2010                        NCT01519791‡‡               January 2012      CZP           MTX               213--655

                        RA-BEGIN§, ¶, ††        ^[@R26]^     2010                        NCT01711359                 January 2013      BAR           MTX               210--215

  MTX IR                European IL-1Ra§§       ^[@R27]^     1987                        --                          --                ANA           PBO               116--121

                        ATTRACT                 ^[@R28]^     1987                        --                          March 1997        IFX           MTX               88--87

                        DE-O19                  ^[@R29]^     1987                        --                          February 2000     ADA           MTX               200--212

                        AIM                     ^[@R30]^     1987                        NTC00048568                 November 2002     ABA           MTX               219--433

                        LITHE‡, ¶¶              ^[@R31]^     1987                        NCT00106535                 December 2004     TCZ           MTX               393--399

                        RAPID 1                 ^[@R32]^     1987                        NCT00152386                 February 2005     CZP           MTX               199--393

                        RAPID 2¶¶               ^[@R33]^     1987                        NCT00175877                 June 2005         CZP           MTX               127--246

                        GO-FORWARD              ^[@R34]^     1987                        NCT00264550                 November 2005     GOL           MTX               133--133

                        GO-FORTH                ^[@R36]^     1987                        NCT00727987                 May 2008          GOL           MTX               88--87

                        CAMEO\*\*               ^[@R37]^     1987                        NCT00654368                 June 2008         ETN           MTX               104--94

                        J-RAPID¶¶               ^[@R38]^     1987                        NCT00791999                 November 2008     CZP           MTX               77--85

                        ACT-RAY‡, ¶, \*\*       ^[@R39]^     1987                        NCT00810199                 March 2009        TCZ           MTX               276--277

                        ORAL-SCAN¶¶             ^[@R40]^     1987                        NCT00847613                 March 2009        TOF           PBO               79--321

                        GO-FURTHER              ^[@R41]^     1987                        NCT00973479                 September 2009    GOL           MTX               197--395

                        AMPLE\*\*\*             ^[@R42]^     1987                        NCT00929864                 October 2009      ABA           ADA               328--318

                        DRIVE                   ^[@R43]^     1987                        JapicCTI-101 263            August 2010       DNM           MTX               88--87

                        PLANETRA†††             ^[@R44]^     1987                        NCT01217086                 October 2010\*    CPT13         IFX               304--302

                        MOBILITY¶¶              ^[@R45]^     1987                        NCT01061736                 March 2011        SAR           MTX               398--400

                        RA-BEAM \*\*\*          ^[@R46]^     2010                        NCT01710358                 November 2012     BAR           MTX               488--487

                        SB4§§, †††              ^[@R47]^     2010                        NCT01895309                 June 2013\*       SB4           ETN               297--299

                        SB2§§, †††              ^[@R48]^     2010                        NCT01936181                 August 2013\*     SB2           IFX               293--291

                        RAJ4                    ^[@R49]^     2010                        NCT02305849                 July 2014\*       PEF           MTX               170--175

                        SELECT-COMPARE \*\*\*   ^[@R50]^     2010                        NCT02629159                 December 2015\*   UPA           MTX               651--651

  DMARDs IR             MN301                   ^[@R11]^     1987                        --                          1994              LEF           PBO, SSZ          91--134

                        TEMPO¶                  ^[@R51]^     1987                        --                          October 2000      ETN           MTX               228--231

                        SAMURAI                 ^[@R52]^     1987                        --                          March 2003        TCZ           DMARDs            148--158

                        GO-MONO                 ^[@R53]^     1987                        --                          May 2008          GOL           PBO               105--102

                        HIKARI‡                 ^[@R54]^     1987                        NCT00791921‡‡‡              November 2008     CZP           DMARDs§§§         114--116

                        J-ETA§§                 ^[@R55]^     1987                        --                          --                ETN           MTX               176--192

                        BREVACTA¶¶              ^[@R56]^     1987                        NCT01232569                 March 2011        TCZ           DMARDs            219--437

                        SURROUND-D              ^[@R57]^     2010                        NCT01604343                 July 2012         SIR           DMRADs            556--557

                        RA-BUILD                ^[@R58]^     2010                        NCT01721057                 January 2013      BAR           DMARDs            228--229

  TNFi IR               REFLEX                  ^[@R59]^     1987                        NCT00468546                 July 2003         RTX           MTX               209--308

                        ADMIRE\*\*              ^[@R60]^     1987                        NCT00808509                 January 2009      ADA           MTX               16--17

                        REASSURE                ^[@R61]^     2010                        NCT01377012                 August 2011\*     SEC           MTX               214--213
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*If the patient's enrollment date could not be confirmed in the paper, it was replaced by the trial start date from the ClinicalTrials.Gov site.

†If the trial had multiple arms, the active drug group including the largest population of patients was marked as active in the table.

‡If the trial had multiple investigation periods/phases, the data for period/phase-1 or double-blind period data were only recorded.

§This trial permitted MTX user who had not received it more than 3 weekly.

¶This trial included a comparative study between monotherapy and combination therapy.

\*\*This trial included a withdrawal or tapering study of active drug.

††DMARD-naïve patients were included.

‡‡This trial had two periods. In the case of withdrawal study period, the clinical trial number is NCT01521923.

§§This was not a trial name.

¶¶This trial included biological DMARDs user.

\*\*\*This trial included a head to head study.

†††This was a non-inferiority trial of biosimilar drug.

‡‡‡This trial had two periods. In the case of open-label period, the clinical trial number is NCT00791921.

§§§DMARDs, other than MTX and leflunomide, were defined as comparator drugs.

ABA, abatacept; ADA, adalimumab; ANA, anakinra; BAR, baricitinib; CT-P13, biosimilar of infliximab; CZP, certolizumab; DNM, denosumab; DMARDs, disease-modifying antirheumatic drugs; ETN, etanercept; GOL, golimumab; IFX, infliximab; IR, inadequate responder; LEF, leflunomide; MTX, methotrexate; NR, not reported; PBO, placebo; PEF, peficitinib; RA, rheumatoid arthritis; RTX, rituximab; SAR, sarilumab; SB2, biosimilar of infliximab; SB4, biosimilar of etanercept; SEC, secukinumab; SIR, sirukumab; TCZ, tocilizumab; TNF, tumor necrosis factor; TOF, tofacitinib; UPA, upadacitinib.

Main patient characteristics at baseline {#s7-s1}
----------------------------------------

The main baseline demographic and clinical characteristics of the patients included in the 52 trials are reported in [table 2](#T2){ref-type="table"}. MTX-naïve trials generally included patients with short disease duration (mean duration per treatment group was less than a year), while MTX IR trials had a longer mean disease duration per treatment arm (1.7--11 years). Rheumatoid factor (RF) positivity was reported in 48 out of 52 trials (92.3%), and anti-citrullinated protein antibody (ACPA) positivity was described in 20 out of 52 trials (38.5%). In recent trials, the proportion of RF or ACPA positive patients increased ([online supplementary figure 2](#SP1){ref-type="supplementary-material"}). The majority of patients has high level of disease activity ([table 2](#T2){ref-type="table"}).

###### 

Baseline demographic and clinical characteristics of the patients\*

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients population   Trial name        Disease duration, years†   RF positivity, %   DMARDs failed, number, %   DMARD naïve, %   Taking steroids, %   CRP, mg/dL     ESR, mm/h        DAS28‡          SJC,\               HAQ DI         Total radiographic score
                                                                                                                                                                                                         number/66 joints§                  
  --------------------- ----------------- -------------------------- ------------------ -------------------------- ---------------- -------------------- -------------- ---------------- --------------- ------------------- -------------- --------------------------
  MTX naïve             US301/ULTRA       6.5--7.0                   59--65             0.8--0.9                   40--45           53--55               1.9--2.5       33.8--38.4       \-              13.0--14.8§         1.3            22.8--25.4

                        MN302             3.7--3.8                   74--76             1.1                        33--34           45--49               4.1--4.2       51.0--51.6       \-              15.8--16.5§         1.5            24.6--24.9

                        ERA               1.0                        87--89             0.5--0.6                   54--61           39--42               3.3--4.4       \-               \-              24.0                \-             11.2--12.9

                        ASPIRE            0.8--0.9                   71--73             0.0                        65--68           37--39               2.6--3.0       43.0--45.0       6.6--6.8        21.0--22.0          1.5            11.2--11.6

                        PREMIER           0.7--0.8                   84--85             \-                         67--69           35--37               3.9--4.1       \-               6.3--6.4        21.1--22.1          1.5--1.6       18.1--21.9

                        COMET             0.7--0.8                   67--70¶            \-                         22--76           49--50               3.6--3.7       47.8--49.3       6.5             17.1--17.6          1.6-.17        \-

                        GO-BEFORE         1.0--1.8                   76--82             \-                         42--50           64--70               1.3--1.4       36.0--40.0       6.1--6.4        11.0--14.0          1.5--1.8       18.2--20.4

                        IMAGE             0.9--1.0                   85--87             \-                         69--72           44--48               3.0--3.4       \-               7.0--7.1        20.0--22.4          1.7--1.8       6.9--7.7

                        OPTIMA            4.0--4.5†                  87--89             \-                         89--90           41--46               2.7--3.0       \-               6.0C^RP^        18.0                1.6            11.2--11.8

                        AGREE             6.2--6.7†                  96--97             \-                         96--97           49--51               3.1--3.6       \-               6.2--6.3C^RP^   21.9--22.9          1.7            6.7--7.5

                        HOPEFUL 1         0.3                        83--85             \-                         43--53           30--34               2.9--3.1       59.9--61.8       6.6             16.5--17.3          1.1--1.3       13.6

                        FUNCTION          0.4--0.5                   89--91             \-                         76--82           33--40               2.3--2.6       50.4--55.7       6.6--6.7        16.1--17.6          1.5--1.6       5.7--7.7

                        PRIZE             2.9--3.5†                  55--63             \-                         74--88           29--52               1.1--1.2       \-               5.7--5.9        9.4--11.2           1.1--1.2       7.6--8.5

                        ORAL Start        2.7--3.4                   82--84             \-                         60--63           \-                   2.0--2.6       53.4--56.0       6.5--6.6        15.6--16.8          1.5            16.1--19.1

                        C-OPERA           4.0--4.3†                  93--96             \-                         81--82           16--20               1.3--1.5       38.4--43.7       5.4--5.5        8.3--8.4§           1.0--1.1       5.2--6.0

                        C-EARLY           2.9†                       97                 0.0                        100              30--34               1.1            42.0--44.0       6.7--6.8        12.4--13.0§         1.6--1.7       7.2--8.5

                        RA-BEGIN          1.3--1.9                   95--97             0.0                        90--92           30--39               2.2--2.4       49.0--54.0       6.6             16.0                1.6--1.7       11.4--13.3

  MTX IR                European IL-1Ra   3.7--4.3                   69--71             \-                         19--34           41                   4--4.2         46.8--53.2       \-              25.6--26.6          1.5--1.6       24.7--29.6/12.0--16.6

                        ATTRACT           9.0--12.0                  77--84             2.5--2·8                   \-               54--65               3.3--4.2       49.0--52.0       \-              21.0--24.0          1.7--1.8       66.6--81.9

                        DE-O19            10.9--11.0                 81--90             2.4                        \-               \-                   1.4--1.8       \-               \-              19.0--19.6          1.4            66.4--72.1

                        AIM               8.5--8.9                   79--82             \-                         88--91           69--72               2.8--3.3       \-               6.4             22.1--21.4          1.7            44.5--44.9

                        LITHE             9.0--9.4                   81--83             1.6--1.7                   22--19           62--70               2.1--2.3       45.9--46.5       6.5--6.6        16.6--17.3          1.5            28.5--28.7

                        RAPID 1           6.1--6.2                   80--84             1.3--1.4                   \-               \-                   1.4--1.6\*\*   42.5--45.0\*\*   6.9--7.0\*\*    21.2.21.7           1.7            27.0--27.5

                        RAPID 2           5.6--6.5                   76--78             1.2--1.3                   \-               55--62               1.3--1.4       39.1--43.7       6.8--6.9        20.5--21.9          1.6            39.6--46.7

                        GO-FORWARD        4.5--6.7\*\*               81--87             \-                         \-               65--75               0.8--1.0\*\*   34.0--37.0\*\*   5.9--6.1\*\*    11.0--13.0\*\*      1.3--1.4\*\*   29.7--39.6\*\*

                        GO-FORTH          8.1--8.8                   \-                 \-                         \-               \-                   1.5--2.2       \-               5.5--5.6        11.4--11.8          0.9--1.0       53.2--58.0

                        CAMEO             9.0--9.3                   61--68             1.0                        \-               74--78               1.2--1.3       21.8--23.0       5.4--5.4        9.7--10.3§          1.3--1.5       37.9--38.2

                        J-RAPID           5.6--6.0                   86--90             1.7--1.8                   \-               60--69               1.3--1.6       44.5--49.0       6.2--6.5        16.6--18.4          1.1--1.2       49.9--54.8

                        ACT-RAY           8.2--8.3                   \-                 1.9                        \-               49                                  \-               6.3--6.4        14.4--15.3          1.5            30.4--37.1

                        ORAL-SCAN         8.8--9.5                   75--80             \-                         24--42           \-                   1.2--1.7       47.8--54.5       6.2--6.3        14.1--14.5          1.2--1.4       30.1--37.3

                        GO-FURTHER        6.9--7.0                   100.0††            \-                         0                \-                   2.2--2.8       \-               5.9--6.0C^RP^   14.8--15.0          1.6--1.6       47.6--50.3

                        AMPLE             1.7--1.9                   76--77             \-                         0                50--51               1.5--1.6       \-               5.5C^RP^        15.8--15.9          1.5            24.2--24.8

                        DRIVE             2.2--2.3                   67--69             \-                         74--82           42--45               0.5--0.8       \-               3.6--4.0C^RP^   8.9--10.5           0.3--0.5       10.0--13.6

                        PLANETRA          1.7--1.9                   72--75             \-                         0                \-                   1.9            46.6--48.5       5.8--5.9        15.2--16.2          1.6            68.3--64.8

                        MOBILITY          8.6--9.5                   83--87             \-                         0                63--67               2.0--2.4       \-               5.9--6.0C^RP^   16.6--16.8          1.6--1.7       46.3--54.7

                        RA-BEAM           10.0                       90--91             \-                         0                56--61               2.0--2.2       48.0--49.0       6.4--6.5        15.0--16.0          1.55--1.59     43.0--45.0

                        SB4               6.0--6.2                   78--79             \-                         0                \-                   1.3--1.5       46.4--46.5       6.5             15.0--15.4          1.49--1.51     38.9--43.3

                        SB2               6.3--6.6                   71--74             \-                         0                \-                   1.6--1.4       44.5--46.7       6.5             14.6--14.9          1.5            37.1--38.9

                        RAJ4              4.3--4.4                   \-                 \-                         0                \-                   2.5--2.6       51.0--53.8       5.8--6.1        6.8--7.0            0.91--1.05     25.0--28.4

                        SELECT-COMPARE    8.0                        87--88             \-                         0                60--62               1.8--2.0       \-               6.4--6.5        16.0--17.0          1.6            34.0--36.0

                        MN301             5.7--7.6                   76--83             0.8--1.0                   40--53           45--46               3.4--4.5       50.5--55.7       \-              15.3--16.2§         1.7--1.9       41.9--46.3

  DMARD IR              TEMPO             6.3--6.8                   71--76             2.3                        0                57--64               2.5--3.2       \-               5.5--5.7        22.1--23.0          1.8            28.8--35.5

                        SAMURAI           2.2--2.4                   51                 2.7--2.8                   35               \-                   4.7--4.9       70.8--71.0       6.4--6.5        11.9--12.5          \-             28.3--30.6

                        GO-MONO           8.1--9.4                   \-                                            0                \-                   2.2--2.6       \-               5.8--6.0        12.6--13.1          1.0--1.1       43.8--56.9

                        HIKARI            5.4--5.8                   85--89             1.8--1.9                   0                66--71               1.6--1.7       49.0--51.0       6.1--6.3        13.8--15.5          1.1--1.2       36.5--46.1

                        J-ETA             2.9--3.0                   76--78             \-                         0                60--67               2.1--2.3       42.0--43.7       5.7--5.8        13.8--14.2          1.0--1.2       25.1--31.4

                        BREVACTA          11.1--11.1                 81--82             1.3--1.4                   0                \-                   1.9--2.0       49.4--50.9       6.6--6.7        17.5--17.6          1.6--1.6       59.0--60.4

                        SURROUND-D        8.3--8.8                   78--80             \-                         0                59--65               2.4--2.5       \-               \-              \-                  1.5--1.6       41.8--42.5

                        RA-BUILD          7.0--8.0                   75--77             \-                         0                50--51               1.4--1.8       23.0--25.0       6.2--6.3        13.0--14.0          1.5--1.6       19.0--26.0

  TNFi IR               REFLEX            11.7--12.1                 79                 2.4--2.6                   0                61--65               3.7--3.8       48.0--48.4       6.8--6.9        22.9--23.4          1.9--1.8       47.9--48.3

                        ADMIRE            7.6--10.4\*\*              69--92             2.0                        0                \-                   1.7--2.1\*\*   \-               2.1--1.7\*\*    \-                  0.1--0.4\*\*   22.5--42.5\*\*

                        REASSURE          7.8--9.0                   91--94             \-                         0                58--62               \-             \-               5.6--5.7        16.4--17.2          1.7            48.1--57.7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Values were expressed in mean unless otherwise indicated. The range of values was from the minimum to maximum, incorporating all study arms.

†If the disease duration was expressed as months, it is indicated.

DAS28 was based on the ESR.

§If the swollen-joints count was based on 28 joint examinations, it is indicated.

This value meant anti-citrullinated protein antibody positivity.

\*\*Values were expressed in median.

††This trial included patients who was positive either in rheumatoid factor or anti-citrullinated protein antibody.

CRP, C reactive protein; DAS28, the 28-joint disease activity score; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ-DI, health assessment questionnaire-disability index; IR, inadequate responder; MTX, methotrexate; RF, rheumatoid factor; SB2, biosimilar of infliximab; SB4, biosimilar of etanercept; SJC, swollen joints count; TNF, tumour necrosis factor.

Scoring methodology {#s7-s2}
-------------------

The description of the radiographic methodology used in each trial is shown in [table 3](#T3){ref-type="table"}. Conventional radiography (CR) of hands and feet was performed in all trials, except for IL-1Ra, where only hands were included. CRs were usually evaluated by two readers. However, several trials, such as leflunomide trials,^[@R11]^ IL1-Ra,^[@R27]^ PRIZE^[@R22]^ and CAMEO^[@R37]^ trial, only one reader scored CRs. When CRs were scored by two readers, the average score of the two readers was reported. The inter-reader and intra-reader intraclass correlation coefficients of status scores were reported in several RCTs and showed a high reliability of the measurements between readers and within a reader. The readers employed the Sharp method, the van der Heijde modification of the Sharp (SvdH) method or the Genant modification of the Sharp (GS) method. All methods include separate scores for erosions (ES) and joint space narrowing (JSN) that add to a total score. The maximum total score is 398 for the Sharp method, 448 for the SvdH and 290 for the GS method. Results were reported for the total score, as well as for the separate scores, per treatment arm. The change (Δ) in radiographic scores, which represents the difference between the scores at the follow-up visit and the scores at baseline, was the main outcome. A variety of approaches were used to deal with missing data, including linear extrapolation (LE), last observation carried forward and multiple imputation methods. For the patients who withdrew early or who received rescue medication, CR scores were usually estimated by LE of the scores from the radiographs taken at an early visit.

###### 

Radiographic methodology and statistical analysis in each trial

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients\    Trial name       Scoring method   Interval radiographs\*               Number of readers   Inter-/intra reader agreement   Assessment of agreement   SDC/SDD                                  Impution methods   Sensitivity analysis                                    
  population                                                                                                                                                                                                                                                                            
  ------------ ---------------- ---------------- ------------------------------------ ------------------- ------------------------------- ------------------------- ---------------------------------------- ------------------ ---------------------- -------------------------------- ------
  MTX naïve    US301            Sharp            0, 1 year, (2 years)                 1                   0.972, 0.971†                   \-                        \-                                       No                 No                     \-                               Yes‡

               MN302            Sharp            0, 1 year, (2 years)                 1                   0.972, 0.971†                   \-                        \-                                       No                 Yes                    \-                               Yes‡

               ERA              Sharp            0, 6 months, 1 year, (2,4,5 years)   2 of 6              0.85/-                          ICC                       \-                                       Yes                No                     \-                               \-

               ASPIRE           SvdH             0, 30 weeks, 1 year                  2                   \-                              \-                        SDD\                                     Yes                No                     Unconditional mean imputation§   \-
                                                                                                                                                                    (0.93 at week 54)                                                                                                   

               PREMIER          Sharp            0, 6 months, 1 year, (2, 5 years)    2 of 4              \-                              \-                        \-                                       \-                 No                     \-                               \-

               COMET            SvdH             0, 1 year, 2 years                   2                   0.935/0.961                     ICC                       \-                                       Yes                No                     \-                               \-

               GO-BEFORE        SvdH             0, 28 weeks, 1 year, (2, 5 years)    2                   -/0.90                          ICC                       SDC\                                     Yes                No                     \-                               \-
                                                                                                                                                                    (2.7 at week 52)                                                                                                    

               IMAGE            Genant           0, 6 months, 1 year, (2 years)       2                   \-                              \-                        \-                                       Yes                No                     \-                               Yes

               OPTIMA           SvdH             0, 26 weeks, 78 weeks                2                   \-                              \-                        \-                                       No                 No                     MI¶                              \-

               AGREE            Genant           0, 6 months, 1 year, (2 years)       \-                  \-                              \-                        \-                                       Yes                No                     \-                               Yes

               HOPEFUL 1        Sharp            0, 6 months                          2                   \-                              \-                        \-                                       Yes                No                     \-                               \-

               FUNCTION         SvdH             0, 6 months, 1 year, (2 years)       \-                  \-                              \-                        \-                                       Yes                No                     \-                               Yes

               PRIZE            SvdH             0\*\*, 39weeks\*\*,65weeks\*\*       1                   \-                              \-                        \-                                       No                 Yes                    \-                               \-

               ORAL Start       SvdH             0, 6 months, 1 year, 2 years         2                   \-                              \-                        \-                                       Yes                No                     \-                               Yes

               C-OPERA          SvdH             0, 6 months, 1 year                  2                   \-                              \-                        \-                                       Yes                No                     \-                               \-

               C-EARLY          SvdH             0, 1 year                            2                   \-                              \-                        \-                                       Yes                No                     \-                               \-

               RA-BEGIN         SvdH             0, 6 months, 1 year                  2                   \-                              \-                        SDC (1.15 at week 24, 1.41 at week 52)   Yes                No                     \-                               Yes

  MTX IR       IL-1RA           Genant           0, 6 months, 1 year                  1                   \-                              \-                        \-                                       Yes                Yes                    \-                               Yes‡

               ATTRACT          SvdH             0, 7 months, 1 year, (2 years)       2                   0.89/-                          ICC                       \-                                       No                 No                     CMI††                            Yes

               DE-O19           Sharp            0, 6 months, 1 year, (3, 5 years)    2                   \-                              \-                        \-                                       Yes                Yes                    \-                               Yes

               AIM              Genant           0, 1 year, (2 years, 5 years)        2                   0.9/-                           ICC                       \-                                       Yes                No                     \-                               Yes

               LITHE            Genant           0, 6 months, 1 year, (2, 5yrears)    2                   \-                              \-                        \-                                       Yes                No                     \-                               Yes

               RAPID 1          SvdH             0, 6 months, 1 year, (2 years)       2 of 3              \-                              \-                        \-                                       Yes                Yes                    \-                               Yes

               RAPID 2          SvdH             0, 6 months, (2 years, 3 years)      2                   \-                              \-                        \-                                       Yes                Yes                    \-                               Yes

               GO-FORWARD       SvdH             0, 6 months, 1 year, (2 years)       2                   -/0.95                          ICC                       SDC\                                     Yes                No                     \-                               \-
                                                                                                                                                                    (1.8 at 52 week)                                                                                                    

               GO-FORTH         SvdH             0, 6 months, (3 years)               2                   0.98, 0.80‡‡                    ICC                       SDC\                                     No                 No                     \-                               \-
                                                                                                                                                                    (3.23 at 24 week)                                                                                                   

               CAMEO            SvdH             0, 1 year, 2 years                   1                                                                             \-                                       No                 Yes                    \-                               Yes

               J-RAPID          SvdH             0, 6 months                          2                   \-                              \-                        \-                                       Yes                No                     \-                               \-

               ACT-RAY          Genant           0, 6 months, 1 year, (2 years)       2                   \-                              \-                        SDC\                                     No                 Yes                                                     \-
                                                                                                                                                                    (1.5 at 52 week)                                                                                                    

               ORAL-SCAN        SvdH             0, 6 months, 1 year, 2 years         2                   \-                              \-                        \-                                       Yes                No                     GEE, RCM                         Yes

               GO-FURTHER       SvdH             0, 6 months, 1 year, (2 years)       2                   0.76/0.97                       ICC                       SDC\                                     Yes                Yes                    \-                               Yes
                                                                                                                                                                    (1.91 at 52 week)                                                                                                   

               AMPLE            SvdH             0, 1 year                            2                   \-                              ICC                       SDC\                                     Yes                No                     \-                               \-
                                                                                                                                                                    (2.8 at 52 week)                                                                                                    

               DRIVE            SvdH             0, 6 months, 1 year                  \-                  \-                              \-                        \-                                       Yes                No                     \-                               \-

               PLANETRA         SvdH             0, 1 year                            2                   \-                              \-                        \-                                       Yes                No                     \-                               \-

               MOBILITY         SvdH             0, 6 months, 1 year, (2 years)       2                   \-                              \-                        \-                                       Yes                Yes                    \-                               Yes

               RA-BEAM          SvdH             0, 6 months, 1 year                  2                   \-                              \-                        SDC (1.22 at 24 week)\                   Yes                Yes                    MMRM                             Yes
                                                                                                                                                                    (1.47 at 52 week)                                                                                                   

               SB4              SvdH             0, 1 year                            2                   \-                              \-                        SDC\                                     No                 No                     \-                               \-
                                                                                                                                                                    (2.3 at 52 week)                                                                                                    

               SB2              SvdH             0, 1 year                            2                   \-                              \-                        \-                                       No                 No                     \-                               \-

               RAJ4             SvdH             0, 6 months, 1 year                  2                   \-                              \-                        \-                                       Yes                No                     \-                               Yes

               SELECT-COMPARE   SvdH             0, 3 months, 6 months                2                   \-                              \-                        \-                                       Yes                No                     \-                               Yes

  DMARD IR     MN301            Sharp            0, 6 months, 1 year, (2 years)       1                   \-                              \-                        \-                                       No                 Yes                    \-                               Yes‡

               TEMPO            SvdH             0, 6 months, 1 year, (2, 3 years)    2                   0.85--0.98/0.90--0.99           ICC                       SDD\                                     Yes                Yes                    \-                               Yes‡
                                                                                                                                                                    (6.2 at 52 week)                                                                                                    

               SAMURAI          SvdH             0, 6 months, 1 year                  2                   0.96--0.98/0.99                 ICC                       \-                                       Yes                No                     \-                               \-

               GO-MONO          SvdH             0, 6 months, (52, 104, 120 weeks)    2                   0.98, 0.80/                     ICC                       \-                                       No                 No                     Median change§§                  \-

               HIKARI           SvdH             0, 6 months, 1 year                  2                   \-                              \-                        \-                                       Yes                No                     \-                               \-

               J-ETA            SvdH             0, 6 months, 1 year                  2                   \-                              \-                        SDD                                      Yes                No                     \-                               \-

               BREVACTA         SvdH             0, 6 months, 72 weeks                \-                  \-                              \-                        \-                                       Yes                No                     \-                               Yes

               SURROUND-D       SvdH             0, 18 weeks, 6 months, 1 year        \-                  \-                              \-                        \-                                       Yes                No                     \-                               \-

               RA-BUILD         SvdH             0, 6 months                          2                   \-                              \-                        SDC\                                     Yes                Yes                    \-                               \-
                                                                                                                                                                    (1.2 at 24 week)                                                                                                    

  TNFi IR      REFLEX           Genant           0, 6 months, 1 year, (2, 5 years)    2                   \-                              \-                        \-                                       Yes                No                     \-                               Yes

               ADMIRE           SvdH             0, 28 weeks, 1 year                  \-                  \-                              \-                        \-                                       No                 No                     \-                               \-

               REASSURE         SvdH             0, 1 year, (2 years)                 \-                  \-                              \-                        \-                                       No                 No                     MMRM                             \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Values in parentheses meant X-ray intervals during the long-term extension period.

†Values were correlation coefficients between the duplicate readings of baseline and year-1 radiographs when these were reread along with the year-2 films (correlation coefficient 0.971 for year-1 films and 0.972 for baseline films).

‡Sensitivity analysis was not performed in the primary analysis.

§Missing data was imputed using the change from baseline was estimated using the percentile of the entire patient population.

¶The Markov Chain Monte Carlo method was used to impute the missing radiographic data.

\*\*Radiographs were obtained at baseline (1 year in the open-label phase), 39 weeks (91 weeks in the open-label phase) in the double-blind period.

††Missing data was imputed using group mean change.

‡‡ICC at baseline and week 24 was 0.98 and 0.80, respectively.

§§Changes from baseline in SvdH score for these patients were substituted with the median change for all patients.

CMI, Conditional mean imputation; DMARDs, disease-modifying antirheumatic drugs; GEE, generalised estimating equation; ICC, intra-class correlation coefficient; IR, inadequate responder; LE, linear extrapolation; LOCF, last observation carried forward method; MI, multiple imputation; MMRM, mixed model for repeated measures; RCM, Random coefficients model; SDC, smallest detectable change; SDD, smallest detectable difference; SvdH, van der Heijde modification of the Sharp score; TNF, tumour necrosis factor.

Radiographic results of the trials {#s7-s3}
----------------------------------

[Online supplementary table 1](#SP1){ref-type="supplementary-material"} presents the radiographic outcomes of all 52 trials until 1-year follow-up. The table is organised per scoring method (Genant, Sharp-van der Heijde and Sharp), and thereafter per patient population (MTX-naïve, MTX-IR, DMARD-IR, TNFi-IR). Per arm (intervention and control) the mean (SD), median (IQR) and range of the total score, erosion score and JSN score at baseline is presented. This is followed by the mean (SD) and median (IQR) change scores at 6 months and at 1 year. Finally, the percentage of non-progressors is presented. Non-progression in the RCTs is defined as: the number (%) of patients with ≤3 units of change in erosion scores at follow-up compared with baseline, the number (%) of patients with ≤0 units of change in total, erosion or JSN scores, the number (%) of patients with ≤0.5 units of change in scores, the number (%) of patients with ≤ smallest detectable difference (SDD), the number (%) of patients with ≤ smallest detectable change (SDC). The SDD is defined as the smallest difference between two independent measurements (ie, patients) that can be interpreted as a 'real' difference beyond measurement error, while the SDC represents the SDC beyond measurement between two successive scores of the same patient.^[@R62]^

Of the 52 studies, 37 studies were analysed using the SvdH scoring method. From these, 8 were conducted in early RA (EA) patient populations and 29 were conducted in established patient populations. The baseline total SvdH score were 5--25 in EA trials and 9--79 in established RA trials ([online supplementary figure 3](#SP1){ref-type="supplementary-material"}). In both patient populations, no clear change in baseline total SvdH score was observed over the years.

Long-term extension (LTE) trials {#s7-s4}
--------------------------------

There were 22 LTE trials as shown in [online supplementary table 2](#SP1){ref-type="supplementary-material"}. All trials have a follow-up of 2 years and several an additional follow-up up to 10 years in one trial.

Withdrawal or tapering trials {#s7-s5}
-----------------------------

Finally, the data of the 7 trials that investigated radiographic progression after tapering or withdrawal are summarised in [online supplementary table 3](#SP1){ref-type="supplementary-material"}.

DISCUSSION {#s8}
==========

This is the first overview of radiographic data from all RCTs performed by pharmaceutical companies to obtain registration for new drugs that inhibit radiographic progression in RA or to further support their efficacy. As such this provides a rich source of information for planning future trials with radiographic damage as an outcome.

Fifty-two trials (7 trials used the GS method, 7 the Sharp method and 38 the SvdH method) conducted over 26 years have included a wide variety of RA patient populations. Over time, there has been no significant decline in the mean baseline radiographic score in the RCTs ([online supplementary table 1 and figure 3](#SP1){ref-type="supplementary-material"}). This result is different from the previous study by Rahman *et al.*^[@R6]^ They described a dramatic decrease in severity of RA patients who participated in the TNFi trials. There are several possible explanations on this discrepancy. First, the previous study included only 5 trials in MTX-experienced population. It used to ATTRACT trial^[@R28]^ conducted in 1999 as an anchor study that had the highest baseline radiographic score out of all the trials so far. If ATTRACT trial^[@R28]^ is used as the reference point, the scatter plot is likely to show a negative slope. Second, the actual severity may have decreased, but the clinical trials have adapted the inclusion criteria to select patients with a high propensity for progression. For example, there is a trend that recent trials included more RF or ACPA positive patients. Some trials even required the presence of bone erosions as an inclusion criterion: among 17 trials conducted since 2010, 64.7% of the trials had the mandatory presence of erosions, as compared with 28.6% of the studies prior to 2009. However, overall it is difficult to compare the true trend as data are obtained by different scoring methods and within the same scoring method by different readers. This may all result in variation of the scores, which may challenge the interpretation over time.

In clinical trials, missing values are inevitable. Because missing values can be a potential source of bias, various methods have been proposed to deal with this issue. LE has been the most widely used method in RA clinical trials. In this overview, 37 trials (71.2%), especially the older trials, employed LE methods. However, currently, the use of all available data in mixed models are the preferred method of analysis. For more detail, we refer to the literature.^[@R63]^

In conclusion, we summarised radiographic data from clinical trials used for the registration of drugs for the treatment of RA. This may serve as a repository for designing future clinical trials in RA with structural damage as an endpoint.

###### Key messages

What is already known about this subject?
-----------------------------------------

-   Radiographic progression has been an important outcome assessment in rheumatoid arthritis randomised controlled trials (RCTs).

What does this study add?
-------------------------

-   This is a systematic literature review of the available published information on demographic features, radiographic scoring methods, statistical analyses and detailed radiographic data.

How might this impact on clinical practice?
-------------------------------------------

-   This systematic literature review will help the design of RCTs with the radiographic inhibition claim of new drugs in the future.
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